Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction

Cancer Letters

Volumn 369, Issue 2, 2015, Pages 261-265

  Cheung, Mitchell ^a   Kadariya, Yuwaraj ^a   Talarchek, Jacqueline ^a   Pei, Jianming ^a   Ohar, Jill A ^b   Kayaleh, Omar R ^c   Testa, Joseph R ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Asbestos; BAP1; Cancer predisposition; Familial cancer; Malignant mesothelioma

Indexed keywords

ARTICLE; BAP1 GENE; BASAL CELL CARCINOMA; BENIGN MELANOCYTIC TUMOR; BENIGN TUMOR; CANCER INCIDENCE; CLINICAL ARTICLE; GENE; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; GERMLINE MUTATION; HUMAN; HUMAN TISSUE; MENINGIOMA; MESOTHELIOMA; MULTIPLE CANCER; NONSENSE MUTATION; PRIMARY TUMOR; PRIORITY JOURNAL; ULTRAVIOLET RADIATION; UVEA MELANOMA; DISEASE PREDISPOSITION; GENETICS; INCIDENCE; MELANOMA; METABOLISM; NEOPLASM; PATHOLOGY;

ASBESTOS; BAP1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ASBESTOS; DISEASE SUSCEPTIBILITY; GENE-ENVIRONMENT INTERACTION; GERM-LINE MUTATION; HUMANS; INCIDENCE; MELANOMA; NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84945246801     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.09.011     Document Type: Article

References (29)

1. Henley S.J., Larson T.C., Wu M., Antao V.C., Lewis M., Pinheiro G.A., et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008. Int. J. Occup. Environ. Health 2013, 19:1-10.
2. Flores R.M., Pass H.I., Seshan V.E., Dycoco J., Zakowski M., Carbone M., et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J. Thorac. Cardiovasc. Surg 2008, 135:620-626.
3. Woodman S.E. Metastatic uveal melanoma: biology and emerging treatments. Cancer J. 2012, 18:148-152.
4. Jovanovic P., Mihajlovic M., Djordjevic-Jocic J., Vlajkovic S., Cekic S., Stefanovic V. Ocular melanoma: an overview of the current status. Int. J. Clin. Exp. Pathol 2013, 6:1230-1244.
5. Harbour J.W., Onken M.D., Roberson E.D., Duan S., Cao L., Worley L.A., et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010, 330:1410-1413.
6. Goswami E., Craven V., Dahlstrom D.L., Alexander D., Mowat F. Domestic asbestos exposure: a review of epidemiologic and exposure data. Int. J. Environ. Res. Public Health 2013, 10:5629-5670.
7. Jensen D.E., Proctor M., Marquis S.T., Gardner H.P., Ha S.I., Chodosh L.A., et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998, 16:1097-1112.
8. Bott M., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L., et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet 2011, 43:668-672.
9. Testa J.R., Cheung M., Pei J., Below J.E., Tan Y., Sementino E., et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet 2011, 43:1022-1025.
10. Wiesner T., Obenauf A.C., Murali R., Fried I., Griewank K.G., Ulz P., et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat. Genet 2011, 43:1018-1021.
11. Abdel-Rahman M.H., Pilarski R., Cebulla C.M., Massengill J.B., Christopher B.N., Boru G., et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J. Med. Genet 2011, 48:856-859.
12. Njauw C.N., Kim I., Piris A., Gabree M., Taylor M., Lane A.M., et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS ONE 2012, 7:e35295.
13. Wadt K., Choi J., Chung J.Y., Kiilgaard J., Heegaard S., Drzewiecki K.T., et al. A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma. Pigment Cell Melanoma Res 2012, 25:815-818.
14. Wadt K.A., Aoude L.G., Johansson P., Solinas A., Pritchard A., Crainic O., et al. A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin. Genet 2015, 88(3):267-272. Epub ahead of print.
15. Aoude L.G., Wadt K., Bojesen A., Cruger D., Borg A., Trent J.M., et al. A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers. PLoS ONE 2013, 8:e72144.
16. Cheung M., Talarchek J., Schindeler K., Saraiva E., Penney L.S., Ludman M., et al. Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet 2013, 206:206-210.
17. Faig J., Howard S., Levine E.A., Casselman G., Hesdorffer M., Ohar J.A. Changing pattern in malignant mesothelioma survival. Transl. Oncol 2015, 8:35-39.
18. Xu Z., Armstrong B.K., Blundson B.J., Rogers J.M., Musk A.W., Shilkin K.B. Trends in mortality from malignant mesothelioma of the pleura, and production and use of asbestos in Australia. Med. J. Aust 1985, 143:185-187.
19. Tweedale G. Asbestos and its lethal legacy. Nat. Rev. Cancer 2002, 2:311-315.
20. Ohar J.A., Ampleford E.J., Howard S.E., Sterling D.A. Identification of a mesothelioma phenotype. Respir. Med 2007, 101:503-509.
21. Boscoe F.P., Schymura M.J. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2002. BMC Cancer 2006, 6:264.
22. Xu J., Kadariya Y., Cheung M., Pei J., Talarchek J., Sementino E., et al. Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res 2014, 74:4388-4397.
23. Popova T., Hebert L., Jacquemin V., Gad S., Caux-Moncoutier V., Dubois-d'Enghien C., et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am. J. Hum. Genet 2013, 92:974-980.
24. Farley M.N., Schmidt L.S., Mester J.L., Pena-Llopis S., Pavia-Jimenez A., Christie A., et al. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol. Cancer Res 2013, 11:1061-1071.
25. Testa J.R., Malkin D., Schiffman J.D. Connecting molecular pathways to hereditary cancer risk syndromes. Am. Soc. Clin. Oncol. Educ. Book 2013, 81-90.
26. Rai K., Pilarski R., Cebulla C.M., Abdel-Rahman M.H. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin. Genet 2015, Epub ahead of print. 10.1111/cge.12630.
27. Yoshikawa Y., Sato A., Tsujimura T., Emi M., Morinaga T., Fukuoka K., et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 2012, 103:868-874.
28. Nasu M., Emi M., Pastorino S., Tanji M., Powers A., Luk H., et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J. Thorac. Oncol 2015, 10:565-576.
29. Hisada M., Garber J.E., Fung C.Y., Fraumeni J.F., Li F.P. Multiple primary cancers in families with Li-Fraumeni syndrome. J. Natl Cancer Inst 1998, 90:606-611.